Biotest Aktiengesellschaft (BIO3.DE) Stock
Biotest Aktiengesellschaft

Company profile
Biotest Aktiengesellschaft reported revenue of 726.20 million EUR for fiscal year 2024, and net income of 26.40 million EUR. That is a net profit margin of 3.6% for fiscal year 2024. In Q1 2025 (the quarter ended March 31, 2025) revenue was 124.20 million EUR. Germany was its largest region in fiscal year 2024, with 94% of revenue. In Q1 2025 it reported a net loss of 21.40 million EUR, against net income of 29.50 million EUR a year earlier. Our analysis of its filings shows revenue growing from 516.10 million EUR in fiscal year 2022 to 726.20 million EUR in fiscal year 2024, 18.6% a year on average. Biotest Aktiengesellschaft reports about 2,495 full-time employees.
What stands out
- Revenue turned down in Q1 2025: down 42.3% from a year before, after a rise of 6.1% in fiscal year 2024.
- Net income fell 79.2% in fiscal year 2024, from 127.00 million EUR in fiscal year 2023.
- Revenue in fiscal year 2024 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2024.
About Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest for prophylaxis of the clinical manifestation of cytomegalovirus infection in patients undergoing immunosuppressive therapy; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect CP for prophylaxis and immunoprophylaxis of hepatitis B; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes, as well as autoimmune diseases, including neurological indications, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Guillain-Barré syndrome, immune thrombocytopenia, and Kawasaki syndrome; Varitect for prophylaxis and treatment of varicella zoster virus infections; and Zutectra for prophylaxis and treatment of hepatitis B reinfection following liver transplantation. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company has a technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of Yimmugo, Fibrinogen, and Trimodulin. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols Biotest Holdings GmbH.
Largest shareholders
- Monega Kapitalanlagegesellschaft mbH0.23%
- VM Vermögens-Management GmbH0.08%
- FPS Vermögensverwaltung GmbH0.02%
Share of the company, as of September 25, 2026
Leadership
- Jorg Schuttrumpf — CEO & Chairman of Management Board, 51
- Dirk Schuck — Employee Representative Member of Supervisory Board, 47
- Monika Buttkereit — Head of Investor Relations
- Christina Erb — Head of Corporate HR
How much revenue does Biotest Aktiengesellschaft make?
Biotest Aktiengesellschaft reported 726.20 million EUR in revenue for fiscal year 2024, up 6.1% from 684.60 million EUR in fiscal year 2023. In Q1 2025 revenue was 124.20 million EUR.
Where does Biotest Aktiengesellschaft make most of its revenue?
Germany: 94% of revenue by region in fiscal year 2024, followed by Rest of World (6%).
What companies are similar to Biotest Aktiengesellschaft?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Merck KGaA (MRK.DE), Bayer Aktiengesellschaft (BAYN.DE), Dermapharm Holding SE (DMP.DE), Cannovum Cannabis AG (27N0.DE).
How has Biotest Aktiengesellschaft's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2020, 484.20 million EUR; FY2021, 515.60 million EUR; FY2022, 516.10 million EUR; FY2023, 684.60 million EUR; FY2024, 726.20 million EUR.
Has Biotest Aktiengesellschaft made a profit in recent years?
Net income by fiscal year: FY2020, a loss of 31.80 million EUR; FY2021, a loss of 63.80 million EUR; FY2022, a loss of 32.10 million EUR; FY2023, 127.00 million EUR; FY2024, 26.40 million EUR. It reported a net loss in 3 of these 5 years.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Biotest Aktiengesellschaft (BIO3.DE)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/BIO3.DE